The Neri/Bahlis Lab
Dr. Paola Neri, MD, PhD
Dr. Paola Neri, MD, PhD is an Associate Professor of Medicine, attending physician in the Hematology division at University of Calgary and member of the Arnie Charbonneau Cancer Institute. Since January 2019 she has been the Scientific Director of the Precision Oncology Hub, Translational Research Laboratory, at the Tom Baker Cancer Centre (TBCC) in Calgary.
Dr. Neri received her medical degree at Magna Græcia University, Catanzaro, Italy in 2000. She completed her specialty in Medical Oncology at Magna Græcia University, Catanzaro, Italy in 2005 and received a PhD in Molecular Oncology and Experimental Immunology in 2011. From 2003-2006 she was Rresearch Associate at Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA under the mentorship of Dr. Kenneth Anderson.
In June 2008, Dr. Paola Neri joined the University of Calgary. Together with Dr. Nizar Bahlis, they have established a Myeloma Genome Unit (MGU) that is dedicated to study the myeloma cell genome, transcriptome and epigenome with the aim to develop personalized cancer care delivery and identify mechanisms of drug resistance to novel anti-MM agents.
The focus of Dr. Neri’s research is the study of multiple myeloma (MM) with a particular interest genomic studies with the goal of identifying mechanisms of drug resistance and discovering novel therapeutic targets for this incurable disease.
Dr. Neri is well published in the field and received national and international grants from several agencies including International Myeloma Society, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation and Canadian Institute of Health Research (CIHR).
In 2019 she received the Engineered Air Chair (research funds) in Cancer Research from the University of Calgary. In 2021 she was selected by the International Myeloma Society to receive the Ken Anderson Young Investigator Award for her translational work in multiple myeloma.
She is currently member of the American Society of Hematology, co-chair of Charbonneau Research & Innovation Committee in Calgary and member of Blood Editorial Board, very active both in preclinical and clinical trial research in Myeloma.
